Applied Clinical Trials
With the bevy of coronavirus-specific information, databases and trackers, registries, and other tools out there at the moment, the challenge in store is integrating these resources to help in both clinical care response and informing drug intervention in real-time.
There’s been quite an overwhelming amount of industry-specific information regarding COVID-19 the last few weeks. It appears there are a number of patient registries from specific medical associations, as well as others such as the LabCorp/Ciox Health patient data registry. There are companies offering de-identified data to support clinical care or clinical research decisions, including Ancestry and Cerner. There are clinical trials
Lisa Henderson
service providers, including WCG and Bio-Optronics, offering internal benchmarking data on investigative sites, as well as investigative site survey data from Contiuum Clinical and Clinical SCORE. Consortiums have formed such as the COVID-19 Research Database, a secure repository of HIPAA-compliant, de-identified patient-level data sets, and EndPandemic National Data Consortium, with the goal of integrating data from all ongoing and future clinical studies to accelerate analysis on COVID-19 and SARS-CoV-2 research.
This list is not comprehensive.
Further, Jill Wechsler writes in this article, which as an aside lists even more websites that identify and track research on COVID therapies and vaccines-the many competing resources has led the NIH to form a broad public-private partnership to collaborate on prioritizing and coordinating research on COVID-19 drugs and vaccines.
And that’s where we are. When the dust settles we will have a bevy of COVID-19 clinical trials listing trackers, with patient recruitment matching capabilities, with a number of patient registries, and de-identified patient-level health data sets that don’t talk to each other? The industry has that now, it’s just not COVID-specific. On top of that, is the clear need for integrated real-world evidence to help with both clinical care response, as well as informing therapeutic intervention in real-time.
Our Closing Thought op-ed contributors, Ülo Palm, MD, PhD, senior vice president, digital sciences for
Allergan, and Iya Khalil, PhD, co-founder and CCO, GNS Healthcare, urge the use of AI to get to those more informed evidence and therapeutic decisions, not only in COVID, but moving forward as a whole in drug development. Co-founder and CEO Michelle Longmire, MD, of Medable, in our Q&A, envisions a way forward in drug development where decentralization of trials will lead to less expensive studies that can capture more long-term outcomes data, as well as increased participation, to boost innovation in therapies.
Clearly, we need change. Industry experts and observers have been saying that for years and many calling for disruption. Well, this is disruption. Is industry going to go back to its old ways, or will the pandemic result in lasting positive change?
Lisa Henderson is Editor-in-Chief of Applied Clinical Trials. She can be reached at lhenderson@mmhgroup.com. Follow Lisa on Twitter: @trialsonline
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.